These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20665105)

  • 1. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
    Prieto-Alhambra D; Javaid MK; Servitja S; Arden NK; Martinez-García M; Diez-Perez A; Albanell J; Tusquets I; Nogues X
    Breast Cancer Res Treat; 2011 Feb; 125(3):869-78. PubMed ID: 20665105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
    Khan QJ; Reddy PS; Kimler BF; Sharma P; Baxa SE; O'Dea AP; Klemp JR; Fabian CJ
    Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Servitja S; Nogués X; Prieto-Alhambra D; Martínez-García M; Garrigós L; Peña MJ; de Ramon M; Díez-Pérez A; Albanell J; Tusquets I
    Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.
    Prieto-Alhambra D; Servitja S; Javaid MK; Garrigós L; Arden NK; Cooper C; Albanell J; Tusquets I; Diez-Perez A; Nogues X
    Breast Cancer Res Treat; 2012 Jun; 133(3):1159-67. PubMed ID: 22434523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
    Singh S; Cuzick J; Mesher D; Richmond B; Howell A
    Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
    Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
    Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
    Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
    Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
    Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
    Garcia-Giralt N; Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Torres-Del Pliego E; Balcells S; Albanell J; Grinberg D; Diez-Perez A; Tusquets I; Nogués X
    Breast Cancer Res Treat; 2013 Jul; 140(2):385-95. PubMed ID: 23868189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
    Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
    Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
    Niravath P; Chen B; Chapman JW; Agarwal SK; Welschhans RL; Bongartz T; Kalari KR; Shepherd LE; Bartlett J; Pritchard K; Gelmon K; Hilsenbeck SG; Rimawi MF; Osborne CK; Goss PE; Ingle JN
    Clin Breast Cancer; 2018 Feb; 18(1):78-87. PubMed ID: 29128193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
    Helzlsouer KJ; Gallicchio L; MacDonald R; Wood B; Rushovich E
    Breast Cancer Res Treat; 2012 Jan; 131(1):277-85. PubMed ID: 21904883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
    Niravath P; Hilsenbeck SG; Wang T; Jiralerspong S; Nangia J; Pavlick A; Ademuyiwa F; Frith A; Ma C; Park H; Rigden C; Suresh R; Ellis M; Kent Osborne C; Rimawi MF
    Breast Cancer Res Treat; 2019 Sep; 177(2):427-435. PubMed ID: 31218477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis.
    Karaplis AC; Chouha F; Djandji M; Sampalis JS; Hanley DA
    Ann Pharmacother; 2011 May; 45(5):561-8. PubMed ID: 21521859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.
    Nyrop KA; Muss HB; Hackney B; Cleveland R; Altpeter M; Callahan LF
    J Geriatr Oncol; 2014 Apr; 5(2):148-55. PubMed ID: 24495696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint pain and falls among women with breast cancer on aromatase inhibitors.
    Basal C; Vertosick E; Gillis TA; Li Q; Bao T; Vickers A; Mao JJ
    Support Care Cancer; 2019 Jun; 27(6):2195-2202. PubMed ID: 30306326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
    Kadakia KC; Kidwell KM; Seewald NJ; Snyder CF; Storniolo AM; Otte JL; Flockhart DA; Hayes DF; Stearns V; Henry NL
    Breast Cancer Res Treat; 2017 Jul; 164(2):411-419. PubMed ID: 28451964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.